PeopleBio 2026 Q1 Sales Slightly Up but Losses Continue... Going Concern Uncertainty Noted

Consolidated Q1 2026 revenue KRW 640M (vs 620M in Q1 2025), operating loss KRW 1.72B, net loss KRW 2.05B, continuing losses
Accumulated deficit KRW 97.1B, negative operating cash flow KRW 1.7B, going concern uncertainty noted
Debt ratio 59.4% (consolidated), new short-term borrowings KRW 5B, convertible bonds KRW 10B (book value KRW 7.8B)
R&D expenditure KRW 160M (24.2% of revenue), ongoing marketing and sales expansion
Alzheimer's diagnostics market projected to grow 8.9% CAGR, overseas contracts expanded (Hungary, Thailand, China, etc.)
Small-scale rights offering completed in Apr 2026; co-CEO system (Kang Seong-min, Jeon Yong-beom) adopted in May 2026
Dec 2025 asset acquisition (KRW 98.3B land & building), partially paid via perpetual convertible bond